112 related articles for article (PubMed ID: 2956188)
1. Mechanisms of immunological response induced in CD2F1 mice by administration of semisyngeneic L 1210 leukemia cells treated with cyclophosphamide.
Skórski T; Kawalec M; Kawiak J
Immunol Invest; 1987 Mar; 16(1):33-43. PubMed ID: 2956188
[TBL] [Abstract][Full Text] [Related]
2. Recovery of the ability to induce immune resistance against L1210 lymphatic leukemia in semisyngeneic CD2F1 mice after lethal irradiation and reconstitution with bone marrow purged of leukemia with mafosfamide (ASTA Z 7654).
Skórski T; Kawalec M
Bone Marrow Transplant; 1987 Dec; 2(4):435-40. PubMed ID: 3332191
[TBL] [Abstract][Full Text] [Related]
3. Acceleration of allogeneic antitumor immunity with immune RNA in vitro and T-cell suppression by L1210 tumor bearer spleen cells.
Miura T; Maekawa T; Kurashige S; Mitsuhashi S
Cancer Res; 1981 Feb; 41(2):383-98. PubMed ID: 6160907
[TBL] [Abstract][Full Text] [Related]
4. Cellular composition of spleen and peritoneal exudate in mice after injection of cyclophosphamide-treated L 1210 leukemia cells.
Skórski T; Kawalec M; Kawiak J
Folia Histochem Cytobiol; 1987; 25(1):23-7. PubMed ID: 3305097
[TBL] [Abstract][Full Text] [Related]
5. Effect of carrageenan on the induction of cell-mediated cytotoxic responses in vivo.
Sakemi T; Kuroiwa A; Nomoto K
Immunology; 1980 Oct; 41(2):297-302. PubMed ID: 6969217
[TBL] [Abstract][Full Text] [Related]
6. Development of host-dependent high-grade tumor-specific immunity through a novel mechanism triggered by the Lyt-2+ tumor-specific T cell clone (K7L) that induces temporal growth of L1210 leukemia-K7L-variant.
Nagase F; Ueda K; Kawashima K; Jamshedur Rahman SM; Isobe K; Yoshida T; Hasegawa Y; Ando K; Iwamoto T; Nagura E
J Immunol; 1987 Apr; 138(7):2359-65. PubMed ID: 2951438
[TBL] [Abstract][Full Text] [Related]
7. In vivo potentiation of concanavalin A-bound L1210 vaccine by antimacrophage agents.
Kataoka T; Oh-hashi F; Sakurai Y; Gomi K
Cancer Res; 1980 Oct; 40(10):3832-8. PubMed ID: 6254642
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporin A/VP-16 produced immunity to L1210 leukemia: the participation of cytotoxic CD8 T-lymphocytes.
Slater LM; Sweet P; Stupecky M; Reynolds JT
Clin Immunol Immunopathol; 1995 Jun; 75(3):239-45. PubMed ID: 7768041
[TBL] [Abstract][Full Text] [Related]
9. Depression of afferent arc of the in vivo cytotoxic T-cell immunity by bacterial lipopolysaccharides.
Mizoguchi K; Nakashima I; Hasegawa Y; Isobe K; Kato N; Shimokata K; Kawashima K; Nagase F; Ando K; Yoshida T
Cell Immunol; 1985 Oct; 95(2):330-9. PubMed ID: 2931181
[TBL] [Abstract][Full Text] [Related]
10. Early induction of immune resistance against leukemia in lethally total body irradiated mice reconstituted with syngeneic bone marrow cells obtained from previously immunized donor mice.
Skorski T; Kawalec M; Kawiak J
Bone Marrow Transplant; 1990 Jan; 5(1):23-7. PubMed ID: 2297588
[TBL] [Abstract][Full Text] [Related]
11. Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice.
Glaser M
J Exp Med; 1979 Mar; 149(3):774-9. PubMed ID: 219129
[TBL] [Abstract][Full Text] [Related]
12. Non-cytotoxic activity of pyran copolymer-induced macrophages associated with potentiation of tumour vaccine in recipient mice.
Kataoka T; Oh-hashi F
Cancer Immunol Immunother; 1985; 20(1):69-74. PubMed ID: 2998590
[TBL] [Abstract][Full Text] [Related]
13. Recovery of the in vivo cytotoxic T-cell response in cyclophosphamide-treated mice by injection of mixed-lymphocyte-culture supernatants.
Merluzzi VJ; Kenney RE; Schmid FA; Choi YS; Faanes RB
Cancer Res; 1981 Sep; 41(9 Pt 1):3663-5. PubMed ID: 6790167
[TBL] [Abstract][Full Text] [Related]
14. New application of a stabilized active cyclophosphamide derivative (mafosfamide, ASTA Z 7654)--immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug.
Skórski T; Kawalec M
Invest New Drugs; 1987; 5(2):167-9. PubMed ID: 3654151
[TBL] [Abstract][Full Text] [Related]
15. Immunogenic and nondividing mafosfamide-treated L 1210 cells--comparison of lines resistant and nonresistant to cyclophosphamide.
Kawalec M; Hoser G; Skórski T; Kawiak J
Folia Histochem Cytobiol; 1993; 31(2):63-6. PubMed ID: 8405569
[TBL] [Abstract][Full Text] [Related]
16. Induction of immune resistance against L1210 lymphatic leukemia in mice after chemoradiotherapy of the leukemia and reconstitution with bone marrow purged from the leukemia with mafosfamide.
Skórski T; Kawalec M
Exp Hematol; 1988 Oct; 16(9):782-4. PubMed ID: 3049130
[TBL] [Abstract][Full Text] [Related]
17. Effector mechanisms by which adoptively transferred T cells promote tumor eradication.
Greenberg PD; Kern DE; Jensen MC; Klarnet JP; Cheever MA
Prog Clin Biol Res; 1987; 244():127-35. PubMed ID: 2958868
[No Abstract] [Full Text] [Related]
18. Adoptive suppression of granuloma formation by T lymphocytes and by lymphoid cells sensitive to cyclophosphamide.
Colley DG; Lewis FA; Todd CW
Cell Immunol; 1979 Aug; 46(1):192-200. PubMed ID: 158432
[No Abstract] [Full Text] [Related]
19. Participation of T-lymphocytes in the curative effect of a novel synthetic polyamine analogue, N,N'-bis[3-(ethylamino)propyl]-1,7-heptanediamine, against L1210 leukemia in vivo.
Bowlin TL; Prakash NJ; Edwards ML; Sjoerdsma A
Cancer Res; 1991 Jan; 51(1):62-6. PubMed ID: 1988107
[TBL] [Abstract][Full Text] [Related]
20. Depletion of macrophages expressing I-J antigen results in efficient generation of alloreactive cytotoxic T lymphocytes.
Kobayashi H; Aso H; Ishida N; Maeda H; Pollard RB; Suzuki F
Cell Immunol; 1990 Jul; 128(2):589-602. PubMed ID: 2162738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
